CUN-HAV Enjoy Travel Group
Grupo Hotelero Islazul
Cubasol
Los Portales
Intecap
MITM Events
Cervecería Centroamericana S.A.
Realidad Turística
Centro Nacional de Cirugía de Mínimo Acceso de Cuba
Cuba Energy Summit
Herbalife
Servicios Médicos Cubanos
INTERFER
Instituto Hondureño de Turismo
MAD-HAV Enjoy Travel Group
Agexport
Walmart
MuniGuate
AVA Resorts
INOR
blackanddecker
Barceló Solymar
Nestle

Antibiotics, antivirals, vaccines and anti-inflammatory drugs associated with reduced dementia risk

Date:

Share:

Centro Nacional de Cirugía de Mínimo Acceso de Cuba
Los Portales
AVA Resorts
Cervecería Centroamericana S.A.
Instituto Hondureño de Turismo
Grupo Hotelero Islazul
Herbalife
INTERFER
Intecap
Realidad Turística
Servicios Médicos Cubanos
INOR
MITM Events
blackanddecker
Cuba Energy Summit
Nestle

Estimated reading time: 4 minutes

Antibiotics, antivirals, vaccinations and anti-inflammatory medication are associated with reduced risk of dementia, according to new research that looked at health data from over 130 million individuals.

The study, led by researchers from the universities of Cambridge and Exeter, identified several drugs already licensed and in use that have the potential to be repurposed to treat dementia.

Dementia is a leading cause of death in the UK and can lead to profound distress in the individual and among those caring for them. It has been estimated to have a worldwide economic cost in excess of US$1 trillion dollars.

Despite intensive efforts, progress in identifying drugs that can slow or even prevent dementia has been disappointing. Until recently, dementia drugs were effective only for symptoms and have a modest effect. Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer’s disease – and to slow down progression of the disease, but the National Institute for Health and Care Excellence (NICE) concluded that the benefits were insufficient to justify approval for use within the NHS.

Scientists are increasingly turning to existing drugs to see if they may be repurposed to treat dementia. As the safety profile of these drugs is already known, the move to clinical trials can be accelerated significantly.

    We urgently need new treatments to slow the progress of dementia, if not to prevent it. If we can find drugs that are already licensed for other conditions, then we can get them into trials and – crucially – may be able to make them available to patients much, much faster than we could do for an entirely new drug. The fact they are already available is likely to reduce cost and therefore make them more likely to be approved for use in the NHS.”

    Dr. Ben Underwood, Department of Psychiatry at the University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust

In a study published today in Alzheimer’s and Dementia: Translational Research & Clinical Interventions, Dr Underwood, together with Dr Ilianna Lourida from the University of Exeter, led a systematic review of existing scientific literature to look for evidence of prescription drugs that altered the risk of dementia. Systematic reviews allow researchers to pool several studies where evidence may be weak, or even contradictory, to arrive at more robust conclusions.

In total, the team examined 14 studies that used large clinical datasets and medical records, capturing data from more than 130 million individuals and 1 million dementia cases. Although they found a lack of consistency between studies in identifying individual drugs that affect the risk of dementia, they identified several drug classes associated with altered risk.

One unexpected finding was an association between antibiotics, antivirals and vaccines, and a reduced risk of dementia. This finding supports the hypothesis that common dementias may be triggered by viral or bacterial infections, and supports recent interest in vaccines, such as the BCG vaccine for tuberculosis, and decreased risk of dementia.

Spectroscopy Applications in the Environment eBook eBook Compilation of the top interviews, articles, and news in the last year. Download the latest edition

Anti-inflammatory drugs such as ibuprofen were also found to be associated with reduced risk. Inflammation is increasingly being seen to be a significant contributor to a wide range of diseases, and its role in dementia is supported by the fact that some genes that increase the risk of dementia are part of inflammatory pathways.

The team found conflicting evidence for several classes of drugs, with some blood pressure medications and anti-depressants and, to a lesser extent, diabetes medication associated with a decreased risk of dementia and others associated with increased risk.

Dr Ilianna Lourida from the National Institute for Health and Care Research Applied Research Collaboration South West Peninsula (PenARC), University of Exeter, said: “Because a particular drug is associated with an altered risk of dementia, it doesn’t necessarily mean that it causes or indeed helps in dementia. We know that diabetes increases your risk of dementia, for example, so anyone on medication to manage their glucose levels would naturally also be at a higher risk of dementia – but that doesn’t mean the drug increases your risk.

“It’s important to remember that all drugs have benefits and risks. You should never change your medicine without discussing this first with your doctor, and you should speak to them if you have any concerns.”

The conflicting evidence may also reflect differences in how particular studies were conducted and how data was collected, as well as the fact that different medications even within the same class often target different biological mechanisms.

The UK government is supporting the development of an Alzheimer’s trial platform to evaluate drugs rapidly and efficiently, including repurposed drugs currently used for other conditions.

“Pooling these massive health data sets provides one source of evidence which we can use to help us focus on which drugs we should try first,” said Dr Underwood. “We’re hopeful this will mean we can find some much-needed new treatments for dementia and speed up the process of getting them to patients.” (News Medical Life Sciences)

CUN-HAV Enjoy Travel Group
Los Portales
Nestle
Realidad Turística
Instituto Hondureño de Turismo
Centro Nacional de Cirugía de Mínimo Acceso de Cuba
INOR
MuniGuate
Cervecería Centroamericana S.A.
blackanddecker
MAD-HAV Enjoy Travel Group
Grupo Hotelero Islazul
Cuba Energy Summit
AVA Resorts
INTERFER
Servicios Médicos Cubanos
Barceló Solymar
MITM Events
Herbalife
Walmart
Cubasol
Intecap
Agexport
Maggi - GLUTEN-FREE
Barcelo Guatemala City
Havanatur
Revista Colombiana de Turismo Passport
Blue Diamond Resorts
Hotel Holiday Inn Guatemala
Hotel Barcelo Solymar
MuniGuate
INTERFER
AirEuropa
Cubacel
Henkel Latinoamerica
Intecap

Subscribe to our magazine

━ more like this

Pole Dancing in Israel: A New Dimension with BlueDance.co.il

In recent years, pole dancing has experienced a remarkable transformation, shifting from a misunderstood niche to a popular activity combining fitness, self-expression, and empowerment....

A New Luxury Hotel Just Opened on An Idyllic Beach in Cancun, Mexico — And We Were the First to Stay

Waldorf Astoria Cancun opened to the public on Nov. 1, the brand's first new build in Mexico, with two waterfront pools and a fantastic...

US Lawmakers Join Requests to Extend TPS To Central Americans

The chairman of the US Senate Foreign Relations Committee, Robert Menendez, along with other legislators gathered outside the Capitol this Thursday to express his...

Barbados Airport Receives 54 Flights in One Day

On Saturday, December 21, 54 planes arrived at Barbados’ Grantley Adams International Airport (GAIA), marking a historic milestone for the airport and the tourism...

United Airlines Boosts Flights to Costa Rica’s Guanacaste Airport

Guanacaste Airport, a member of the VINCI Airports network, and the Costa Rican Tourism Board have announced an increase in United Airlines flight frequencies...
Henkel Latinoamerica
Barcelo Guatemala City
Havanatur
Maggi - GLUTEN-FREE
Intecap
Cubacel
AirEuropa
Blue Diamond Resorts
Hotel Barcelo Solymar
INTERFER
Hotel Holiday Inn Guatemala
Revista Colombiana de Turismo Passport

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Agexport
INTERFER
Cubasol
Barceló Solymar
INOR
Cervecería Centroamericana S.A.
Herbalife
Centro Nacional de Cirugía de Mínimo Acceso de Cuba
Grupo Hotelero Islazul
Walmart
Nestle
Servicios Médicos Cubanos
Realidad Turística
MAD-HAV Enjoy Travel Group
AVA Resorts
MITM Events
MuniGuate
Instituto Hondureño de Turismo
Cuba Energy Summit
Los Portales
Intecap
blackanddecker